These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 19217204

  • 1. Targeting the RAF-MEK-ERK pathway in cancer therapy.
    Montagut C, Settleman J.
    Cancer Lett; 2009 Oct 08; 283(2):125-34. PubMed ID: 19217204
    [Abstract] [Full Text] [Related]

  • 2. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ, Der CJ.
    Oncogene; 2007 May 14; 26(22):3291-310. PubMed ID: 17496923
    [Abstract] [Full Text] [Related]

  • 3. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA, Wilhelm S, Carter C, Kelley SL.
    Semin Oncol; 2006 Aug 14; 33(4):392-406. PubMed ID: 16890795
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
    McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT, Steelman LS.
    Curr Opin Investig Drugs; 2008 Jun 14; 9(6):614-30. PubMed ID: 18516761
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Raf: a strategic target for therapeutic development against cancer.
    Beeram M, Patnaik A, Rowinsky EK.
    J Clin Oncol; 2005 Sep 20; 23(27):6771-90. PubMed ID: 16170185
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.
    J Cell Physiol; 2009 Jul 20; 220(1):214-21. PubMed ID: 19288493
    [Abstract] [Full Text] [Related]

  • 11. Is B-Raf a good therapeutic target for melanoma and other malignancies?
    Madhunapantula SV, Robertson GP.
    Cancer Res; 2008 Jan 01; 68(1):5-8. PubMed ID: 18172288
    [Abstract] [Full Text] [Related]

  • 12. The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.
    Yu Z, Ye S, Hu G, Lv M, Tu Z, Zhou K, Li Q.
    Future Med Chem; 2015 Jan 01; 7(3):269-89. PubMed ID: 25826360
    [Abstract] [Full Text] [Related]

  • 13. B-Raf kinase inhibitors for cancer treatment.
    Li N, Batt D, Warmuth M.
    Curr Opin Investig Drugs; 2007 Jun 01; 8(6):452-6. PubMed ID: 17621874
    [Abstract] [Full Text] [Related]

  • 14. Regulation of c-Raf-1: therapeutic implications.
    Beeram M, Patnaik A, Rowinsky EK.
    Clin Adv Hematol Oncol; 2003 Aug 01; 1(8):476-81. PubMed ID: 16258435
    [Abstract] [Full Text] [Related]

  • 15. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models.
    Watanabe K, Tanimura S, Uchiyama A, Sakamoto T, Kawabata T, Ozaki K, Kohno M.
    Clin Cancer Res; 2010 Feb 15; 16(4):1170-8. PubMed ID: 20145173
    [Abstract] [Full Text] [Related]

  • 16. Novel targets in solid tumors: MEK inhibitors.
    Messersmith WA, Hidalgo M, Carducci M, Eckhardt SG.
    Clin Adv Hematol Oncol; 2006 Nov 15; 4(11):831-6. PubMed ID: 17143253
    [Abstract] [Full Text] [Related]

  • 17. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.
    J Pharmacol Exp Ther; 2009 Jun 15; 329(3):1063-70. PubMed ID: 19258520
    [Abstract] [Full Text] [Related]

  • 18. Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.
    Kramer BW, Götz R, Rapp UR.
    BMC Cancer; 2004 Jun 01; 4():24. PubMed ID: 15171791
    [Abstract] [Full Text] [Related]

  • 19. Targeting the ERK signaling pathway in cancer therapy.
    Kohno M, Pouyssegur J.
    Ann Med; 2006 Jun 01; 38(3):200-11. PubMed ID: 16720434
    [Abstract] [Full Text] [Related]

  • 20. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S, Flaherty KT.
    Expert Rev Mol Med; 2012 Oct 12; 14():e17. PubMed ID: 23058743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.